2004
DOI: 10.1016/j.transproceed.2004.07.030
|View full text |Cite
|
Sign up to set email alerts
|

Effect of high-dose intravenous immunoglobulin on suppression of alloantibodies against hla in highly sensitized transplant candidates

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
3
0

Year Published

2005
2005
2014
2014

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 9 publications
(3 citation statements)
references
References 7 publications
0
3
0
Order By: Relevance
“…Immunoabsorption is more costly, invasive, and its availability is limited (23). High‐dose IV IgG has not been shown to be effective in reduce PRAs in similar situations (24). Of course, ongoing immunosuppression is associated with an increased risk of infection.…”
Section: Discussionmentioning
confidence: 99%
“…Immunoabsorption is more costly, invasive, and its availability is limited (23). High‐dose IV IgG has not been shown to be effective in reduce PRAs in similar situations (24). Of course, ongoing immunosuppression is associated with an increased risk of infection.…”
Section: Discussionmentioning
confidence: 99%
“…Due to the multiple pathways of immune modulation effects, IVIGs are used in desensitization procedures and humoral rejection episodes. However, not all treatment effects are satisfactory and in some cases even led to an increase of immunoglobulin levels [10,27,28].…”
Section: Discussionmentioning
confidence: 99%
“…Among the methods that have been used for 'desensitization' of potential transplant recipients, administration of IvIg has played a role for many years. This treatment has been shown to effectively decrease serum antibodies, although it is not uniformly reliable, and was found more effective by some authors (4) than others (5). The principle of successful immune modulation by IvIg in the transplant setting was further supported by data showing an impressive post-transplant treatment response in patients with steroid-resistant rejection (6).…”
mentioning
confidence: 99%